Literature DB >> 19843405

Frequency, timing, and type of prodromal symptoms associated with hereditary angioedema attacks.

Michael J Prematta1, John G Kemp, Joshua G Gibbs, Cathy Mende, Crystal Rhoads, Timothy J Craig.   

Abstract

Hereditary angioedema (HAE) types I and II are autosomal dominant conditions characterized by recurrent attacks of edema formation in the subcutaneous tissue of the body or walls of the upper respiratory or gastrointestinal tract. Frequently, prodromal symptoms occur before an HAE attack. If certain prodromal symptoms were determined to be both sensitive and specific in predicting an acute HAE attack, treatment at the time of the prodrome could prevent development of an attack and decrease morbidity and mortality associated with HAE. The goal is to determine the frequency and timing of prodromal symptoms occurring before HAE attacks. After Institutional Review Board approval, a four-page survey was produced, using a focus group of patients with HAE and was assessed by HAE patients and physicians with expertise in HAE for cognitive reliability. Once devised, the questionnaire was sent to 158 HAE patients. The survey focused on questions related to prodromal symptoms that patients developed before their last HAE attack. Forty-six patients returned the survey and 40 (87.0%) reported the presence of prodromal symptoms before their last HAE attack. Forty-four of 46 (95.7%) reported having had prodromal symptoms before HAE attacks in the past. The most commonly reported prodromal symptoms included unusual fatigue, rash, and muscle aches. Prodromes occur frequently before HAE attacks. This high frequency suggests that prodromal symptoms could be a reliable indication to begin treatment to prevent an acute HAE attack, thus decreasing the anxiety associated with having an HAE attack.

Entities:  

Mesh:

Year:  2009        PMID: 19843405     DOI: 10.2500/aap.2009.30.3279

Source DB:  PubMed          Journal:  Allergy Asthma Proc        ISSN: 1088-5412            Impact factor:   2.587


  10 in total

1.  The complex alteration in the network of IL-17-type cytokines in patients with hereditary angioedema.

Authors:  Francesco Arcoleo; Mariangela Lo Pizzo; Gabriella Misiano; Salvatore Milano; Giuseppina Colonna Romano; Vito Muggeo; Enrico Cillari
Journal:  Clin Exp Med       Date:  2018-04-06       Impact factor: 3.984

Review 2.  [Diagnostics and exclusion of hereditary angioedema : a standarized approach for the practice].

Authors:  M Magerl; J Brasch; U Förster; B Hauswald; E B Mohr; B Mohr; J Prässler; R Treudler; R Vetter; V Wahn; V Zampeli; V Zampelli; M Ziemer; M Maurer
Journal:  Hautarzt       Date:  2012-07       Impact factor: 0.751

3.  A consensus parameter for the evaluation and management of angioedema in the emergency department.

Authors:  Joseph J Moellman; Jonathan A Bernstein; Christopher Lindsell; Aleena Banerji; Paula J Busse; Carlos A Camargo; Sean P Collins; Timothy J Craig; William R Lumry; Richard Nowak; Jesse M Pines; Ali S Raja; Marc Riedl; Michael J Ward; Bruce L Zuraw; Deborah Diercks; Brian Hiestand; Ronna L Campbell; Sandra Schneider; Richard Sinert
Journal:  Acad Emerg Med       Date:  2014-04       Impact factor: 3.451

4.  Cinryze as the first approved C1 inhibitor in the USA for the treatment of hereditary angioedema: approval, efficacy and safety.

Authors:  Michael Lunn; Carah Santos; Timothy Craig
Journal:  J Blood Med       Date:  2010-08-24

Review 5.  Diagnosis and screening of patients with hereditary angioedema in primary care.

Authors:  Maria Paula Henao; Jennifer L Kraschnewski; Theodore Kelbel; Timothy J Craig
Journal:  Ther Clin Risk Manag       Date:  2016-05-02       Impact factor: 2.423

6.  Hereditary Angioedema Type II: First Presentation in Adulthood with Recurrent Severe Abdominal Pain.

Authors:  Mohamed Abuzakouk; Nada AlMahmeed; Esat Memisoglu; Martine McManus; Aydamir Alrakawi
Journal:  Case Reports Immunol       Date:  2018-10-29

7.  Treatment of Hereditary Angioedema: items that need to be addressed in practice parameter.

Authors:  Callie Dagen; Timothy J Craig
Journal:  Allergy Asthma Clin Immunol       Date:  2010-05-25       Impact factor: 3.406

Review 8.  The Story of Angioedema: from Quincke to Bradykinin.

Authors:  Avner Reshef; Mona Kidon; Iris Leibovich
Journal:  Clin Rev Allergy Immunol       Date:  2016-10       Impact factor: 10.817

Review 9.  Differences and Similarities in the Mechanisms and Clinical Expression of Bradykinin-Mediated vs. Mast Cell-Mediated Angioedema.

Authors:  Marcus Maurer; Markus Magerl
Journal:  Clin Rev Allergy Immunol       Date:  2021-02-03       Impact factor: 8.667

10.  Rediscovery of a forgotten disease: Hereditary Angioedema.

Authors:  Okan Gülbahar; Anastasios E Germenis
Journal:  Balkan Med J       Date:  2021-03       Impact factor: 2.021

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.